CD274 and non-small cell lung carcinoma: However, we were able to distinguish differences in OS between HLA-I homozygous and those with maximal heterozygosity in a cohort of 61 patients with advanced NSCLC with PD-L1 ≥ 50% treated with pembrolizumab [10].